Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone for Birch Pollen Induced Allergic Rhinitis
NCT04622917Phase 4Completed
- Sponsor
- Karolinska Institutet
- Start
- Apr 2019
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in allergic rhinitis (AR) comparing Methylprednisolone with Placebo (2 arms). Primary endpoints: Mean Combined Medical- and Symptom score at 3 weeks and Mean symptom score at 3 weeks. Started Apr 2019; status: completed.
02
Drugs
methylprednisolone injection
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT04622917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622917.